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Memory T cells are characterized by their low activation threshold, robust effector func-
tions, and resistance to conventional immunosuppression and costimulation blockade. 
Unlike their naïve counterparts, memory T cells reside in and recirculate through periph-
eral non-lymphoid tissues. Alloreactive memory T cells are subdivided into different 
categories based on their origins, phenotypes, and functions. Recipients whose immune 
systems have been directly exposed to allogeneic major histocompatibility complex 
(MHC) molecules display high affinity alloreactive memory T cells. In the absence of any 
prior exposure to allogeneic MHC molecules, endogenous alloreactive memory T cells 
are regularly generated through microbial infections (heterologous immunity). Regardless 
of their origin, alloreactive memory T cells represent an essential element of the allograft 
rejection process and a major barrier to tolerance induction in clinical transplantation. 
This article describes the different subsets of alloreactive memory T cells involved in 
transplant rejection and examine their generation, functional properties, and mechanisms 
of action. In addition, we discuss strategies developed to target deleterious allospecific 
memory T cells in experimental animal models and clinical settings.
Keywords: memory T cells, allotransplantation, tolerance, heterologous immunity, transplant rejection, immune 
suppression, costimulation blockade
inTRODUCTiOn
Rapid and robust protective responses against previously encountered antigens are beneficial during 
infections, vaccinations, and tumor surveillance. Conversely, memory immune responses against 
donor antigens are detrimental in the context of transplantation and are commonly associated with 
poor graft outcome. The danger of preexisting donor-specific alloantibody (DSA) was recognized 
early in transplant history, and all transplant candidates are tested for the presence of serum DSA 
prior to transplantation. Despite well documented harmful effects of memory T cells in transplanta-
tion (1–4), the potential impact of such cells is mostly neglected while choosing treatment regimens. 
In this review, we initially outline characteristics of alloreactive memory T cells and their functions. 
We also describe existing and emerging strategies designed to delete or suppress memory T cells 
in transplant recipients. To conclude, we discuss future areas of investigation that may translate 
experimental knowledge of alloreactive memory T cells into clinical practice and thus improve 
transplant outcome in sensitized recipients.
Abbreviations: MHC, major histocompatibility complex; APC, antigen-presenting cell; Treg, regulatory T cell; IFNγ, gamma 
interferon; TNFα, tumor necrosis factor alpha; CTL, cytotoxic T lymphocyte; DC, dendritic cell; DSAs, donor-specific 
antibodies.
FigURe 1 | Memory T cell subsets. Abbreviations: Tcm, central memory T cells; Tem, effector memory T cells; Temra, terminally differentiated effector memory T 
cells; Trm, resident memory T cells; Tfh, follicular helper memory T cells.
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BASiC BiOLOgY OF ALLOReACTive 
MeMORY T CeLLS
Origins of Alloreactive Memory T Cells
Laboratory rodents display low frequencies of memory T cells 
(5–10% of all T cells). In the absence of prior exposure to alloan-
tigens, 1–10% of these memory T cells can react to allogeneic 
major histocompatibility complex (MHC) molecules in  vitro 
(5). In mice, these cells called endogenous or natural alloreac-
tive memory T cells recognize intact allogeneic MHC molecules 
through the direct allorecognition pathway (6, 7). It is likely that 
these memory cells are generated through the recognition of 
peptides from commensal bacteria or environmental antigens 
presented by self-MHC, which can mimic complexes formed 
by allogeneic MHC molecules bound to other peptides (8). 
Such antigen mimicry, named “heterologous immunity,” is well 
documented in both humans and experimental animal models. 
Humans and non-human primates raised in a non-sterile envi-
ronment are exposed to more infectious and pro-inflammatory 
agents during their development and thereby likely to develop 
potent heterologous immunity (9). For instance, following an 
EBV infection, HLA-B8+ individuals can become sensitized to 
the allo-MHC molecule HLA-B4402 through antigen mimicry 
resulting from the presentation of some viral or parasitic peptides 
(10, 11).
In laboratory mice, direct sensitization with skin allografts or 
spleen cell immunization is a common approach for generating 
donor-reactive memory T cells. In humans, transplant patients 
can be sensitized from exposures to alloantigens such as previous 
transplants, pregnancies, and blood transfusions. Until now, only 
memory T cells recognizing intact alloantigens directly have been 
reported (2, 12). Yet, it is probable that sensitized patients exhibit-
ing high titers of allospecific antibodies display memory T cells 
recognizing alloantigens indirectly as donor peptides–self-MHC 
complexes.
Memory T cells can also be generated through homeostatic 
proliferation in a lymphopenic environment, including potentially 
alloreactive and pathogenic T cells (13–15). Such homeostatically 
expanded memory T cells can impair tolerance induction to 
allografts (15–17).
The accumulation of alloreactive memory T cells may be 
influenced by the end stage organ disease or treatment common 
in transplant candidates. For example, prolonged exposure to 
dialysis increases the risk of developing alloreactive memory T 
cells (18). In addition, Sawinski et  al. reported that low serum 
levels of 25-OH-vitamin D in dialysis patients correlates with 
the frequency of alloreactive memory T cells independent of age, 
gender, previous transplants, or time on dialysis (19).
Location of Memory T Cells
Memory T cells have been traditionally divided into two 
major subsets with largely overlapping functions but distinct 
trafficking patterns (Figure 1). Central memory T cells (Tcm) 
express lymphoid homing markers CCR7 and CD62L, whereas 
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effector memory T cells (Tem) are CCR7−CD62L− but instead 
express molecules that promote migration into peripheral tis-
sues (20–23). In humans, but not in mice, some memory T cells 
[terminally differentiated effector memory T cells (Temra)] re-
express naive T cell surface marker CD45RA, while downregu-
lating expression of CCR7, CD62L, and CD28, and represent 
a terminal stage of effector differentiation (21, 24, 25). Recent 
studies demonstrated that some T cells in peripheral tissues do 
not circulate and represent a distinct subset of tissue-resident 
memory T cells (Trm) (24, 26–28). Trm cells express early 
activation marker CD69 and αEβ7 integrin CD103 along with 
a number of tissue-specific chemokine receptors (26, 29–32). 
There is accumulating evidence that Trm cells play an important 
role in host protection against infections. It is conceivable that 
Trm cells of both donor and recipient origins may influence 
transplant outcome by facilitating GVHD or allograft rejection, 
respectively. However, the proportion of alloreactive T cells 
among Trm subset and the potential contribution of such cells 
following transplantation remain to be addressed. Another 
important type of memory T cells relevant to transplantation is 
CD4+CXCR5hi follicular helper (Tfh) cells that reside in B cell 
follicles within secondary lymphoid organs and are essential 
for optimal B cell responses and antibody generation (33). As 
memory T cells in secondary lymphoid and non-lymphoid 
peripheral tissues are spared by antibody-mediated lymphoa-
blation (34) Trm cells may be harder to control compared to 
circulating memory T cells.
Low Activation Threshold and Resistance 
to Conventional Costimulatory Blockade
In the process of memory T cell differentiation, the T cell 
receptor and costimulatory signaling cascades are adjusted to 
ensure rapid activation of high magnitude upon antigen reen-
counter (35, 36). This results in the ability of memory T cells to 
respond to lower antigen doses with limited costimulation, i.e., 
to antigen presented by non-professional antigen-presenting 
cells (36–38). While this process is essential for host defense, 
it renders alloreactive memory T cells more dangerous in 
transplant settings. Numerous studies in animal models have 
demonstrated that donor-reactive memory T cells can induce 
allograft rejection despite interruption of essential costimula-
tory pathways, CD28/CD80/CD86 and CD40/CD154 (11, 15, 
39–43).
COnTRiBUTiOn OF MeMORY T CeLLS 
TO ALLOgRAFT ReJeCTiOn AnD 
TOLeRAnCe
Role in Allograft Rejection
During the past decade, studies investigating CD4+ versus CD8+ 
memory T cells revealed that these subsets contribute to allograft 
rejection through distinct mechanisms. Indeed, memory CD4+ 
T cells not only become effector cells upon reactivation, but 
also provide help for the robust activation of donor-reactive 
effector CD8+ T cells (40). These effector CD8+ T cells then are 
the main driving force behind allograft rejection facilitated by 
memory CD4+ T cells in heart-transplanted mice, and CD8+  
T cell depletion or limiting their trafficking into the graft signifi-
cantly extends allograft survival (40, 44).
While de novo responses by naïve T cells can be efficiently 
controlled by current immunosuppression, memory CD4+ 
T cells are resistant to these therapies and can provide help 
for the generation of DSA leading to alloantibody-mediated 
graft injury (40, 44). Recent studies in a mouse model of heart 
transplantation identified potential therapeutic targets to control 
CD40-independent DSA generation by memory CD4+ T cells. 
First, gamma interferon (IFNγ) secretion by memory helper T 
cells is required for de novo DSA generation (45). Second, CD40-
independent helper functions of donor-reactive memory CD4+ 
T cells and heart allograft rejection were markedly inhibited by 
neutralizing B cell activating factor and a proliferation-inducing 
ligand, cytokines critical for B cell survival, activation, and dif-
ferentiation (46).
The fate and functions of donor-reactive memory CD8+ T 
cells following transplantation are equally fascinating. Early 
direct contact of circulating memory CD8+ T cells with donor 
endothelium upregulates the expression of adhesion molecules 
and chemokines thus facilitating infiltration of recipient leu-
kocytes into the graft (47, 48). A proportion of endogenous 
memory CD8+ T cells react to donor MHC class I molecules and 
can infiltrate cardiac allografts within hours after reperfusion. 
Once in the graft parenchyma, these memory CD8+ T cells 
proliferate extensively, upregulate the expression of ICOS, and 
secrete IFNγ in ICOS-dependent manner (49, 50). Although 
this early expression of effector functions was found to be insuf-
ficient to mediate allograft rejection (51), the potential danger 
of endogenous memory CD8+ T cells should not be underes-
timated. The approximation of clinical situation by increasing 
graft cold ischemia storage time enhanced effector functions of 
endogenous memory CD8+ T cells enabling them to promptly 
reject a cardiac allograft despite costimulatory blockade with 
CTLA4-Ig (52).
influence of Memory T Cells on Allograft 
Tolerance
In laboratory rodents, endogenous memory T cells generated 
through heterologous immunity have little ability to prevent 
tolerance induction given that hematopoietic chimerism and/
or costimulation blockade regularly achieve tolerance of fully 
allogeneic transplants (53–55). In contrast, mice that have 
been sensitized to allogeneic MHC through transplantation or 
multiple viral infections become resistant to tolerance induction 
(11, 39, 56, 57). Moreover, naïve mice adoptively transferred 
with alloreactive memory T cells display similar resistance to 
tolerogenesis via hematopoietic chimerism or costimulation 
blockade (11, 39, 56, 57). Therefore, in laboratory rodents, 
antigen-induced rather than endogenous memory T cells 
prevent transplant tolerance. It is still unclear whether this dif-
ference relies on the low frequency of endogenous memory T 
cells or on the fact that these two subsets of memory T cells are 
different in nature.
The presence of memory T cells has been often correlated 
with poor outcomes in clinical transplantation. In humans, the 
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presence of memory T cells pretransplantation has been associ-
ated with an increased risk for acute rejection of kidney trans-
plants (2). However, while EBV- and CMV-specific memory T 
cells displaying alloreactivity have been detected in human trans-
plant recipients, so far there is no indication that the presence of 
“heterologous immunity” in transplant recipients correlates with 
worse graft outcomes (10, 58–60).
Our laboratory showed that a sizable proportion of endog-
enous memory T cells found in peripheral blood, and secondary 
lymphoid organs of naïve cynomolgus monkeys are allospecific. 
Most Tem were CD8+CD95+CD28− IFNγ-producing cells 
located in the spleen, peripheral blood, and bone marrow while 
IL-2-producing Tcm were primarily CD4+CD95+CD28+ and 
limited to the lymph nodes and spleen (12). Based upon this 
observation, we studied the influence of pretransplant memory 
T cell alloreactivity on rejection versus tolerance of kidney 
allografts in monkeys (61). A series of cynomolgus monkeys 
were conditioned [whole body and thymic irradiations + horse 
antithymocyte globulin (ATG) treatment] and received a 
combined kidney and bone marrow transplantation from the 
same allogeneic donor (62). The animals then received a short-
term immunosuppression treatment comprised of anti-CD40L 
antibodies and cyclosporine A (62). This procedure resulted 
in a transient multilineage hematopoietic chimerism and 
achieved long-term survival of kidney allografts (>1 year) after 
withdrawal of immunosuppression in 70% of the monkeys (62). 
On the other hand, approximately 30% of the treated monkeys 
rejected their allograft in an acute fashion within 100–200 days 
posttransplantation (61). In this model, we observed that the 
vast majority of tolerant animals displayed low frequencies of 
donor-reactive memory T cells (61). It is noteworthy that no dif-
ferences between homeostatic expansion of memory T cells were 
observed between monkeys which rejected or accepted kidney 
allografts (61).
Even though memory T cells are generally viewed as 
pathogenic in the context of transplantation, under certain cir-
cumstances, they demonstrate regulatory capacity and suppress 
deleterious pro-inflammatory immune responses. Krupnick et al. 
have reported that early infiltration of central memory CD8+ T 
cells is essential for lung allograft acceptance after treatment with 
CTLA4-Ig and anti-CD154 mAbs (63). Similarly, CD8+CD45RClo 
cells with regulatory properties have been described in rat models 
of solid organ transplantation and GVHD (64, 65). These find-
ings raise a concern that lymphoablative approaches targeting 
memory T cells may interfere with allograft acceptance of certain 
types of transplants.
ReCenT DeveLOPMenTS in TARgeTing 
ALLOReACTive T CeLL MeMORY
Lymphoablation
Induction therapy is widely used in clinical transplantation to 
overcome the deleterious effects of preexisting donor-reactive 
immunity. Antibody-mediated lymphocyte depletion is most 
commonly used induction strategy, particularly in highly sensi-
tized patients and in patients receiving marginal grafts (66–69). 
Although memory T cells are the primary targets of induction 
therapies, they are less susceptible to depletion than naïve T cells 
(70–73). T cells with an effector/memory phenotype are detect-
able after anti-CD52 mAb or ATG induction and are associated 
with acute rejection episodes in non-human primates and human 
transplant recipients (74, 75). In rodents, preexisting memory T 
cells rapidly recover following lymphocyte depletion with ATG 
and dominate anti-donor immune responses. The efficiency of 
memory CD4+ T cell depletion is generally lower than that of 
CD8+ T cells (34, 76–79). Additional depletion of residual CD4+ 
T cells severely impairs the recovery of memory CD8+ T cells 
after ATG treatment (80). Limiting CD4+ T helper signals during 
lymphoablation increases the efficacy of mATG in controlling 
memory T cell expansion and significantly extends heart allo-
graft survival in sensitized recipients (80). These findings are 
consistent with previous observations describing a synergistic 
effect between ATG lymphoablation and costimulatory blockade 
(81, 82).
Alefacept, a fusion protein combining extracellular domain 
of LFA-3 with constant regions of human IgG1 (83–85). LFA-3 
is a ligand for CD2, a molecule that is predominantly detected 
on human T and NK cells. As CD2 expression is upregulated on 
CD45RO+ effector/memory T cells, alefacept selectively depletes 
this subset and spares other T cell populations (86–88). Alefacept 
is currently being used in clinic for the treatment of severe pso-
riasis (89, 90) and is showing promise for targeting alloreactive 
effector/memory T cells in solid organ and bone marrow trans-
plantation (91–95). Most importantly, pretransplant alefacept 
therapy synergizes with CTLA4-Ig presumably by targeting 
costimulatory blockade-resistant CD8+CD2hiCD28− effector/
memory T cells (91).
In addition to direct lymphoablation, manipulating T cell sur-
vival and homeostasis by regulating cell metabolic pathways may 
be a promising therapeutic strategy in transplantation. Recent 
studies suggest that immune cells subsets use different mecha-
nisms of energy generation, and this information can be exploited 
to selectively target undesirable memory T cells [reviewed in Ref. 
(96)].
Costimulatory Blockade
Belatacept, a second generation of CTLA4-Ig, is currently 
used in clinical transplantation to prevent allograft rejection 
and minimize the toxic side effects of calcineurin inhibitors 
(97). Despite reduced side effects and improved graft survival, 
belatacept-treated patients have higher rates of acute cellular 
rejection compared to CNI treatment (98, 99). As memory T 
cells are more resistant to the effects of CTLA4-Ig in animal 
transplantation models, it is possible that presensitized T cells 
could account for some belatacept-resistant rejection episodes. 
Indeed, terminally differentiated memory CD4+ and CD8+ T 
cells in humans (Temra) lose CD28 expression and become 
insensitive to the lack of CD28/B7 costimulation (100–104). 
Not surprisingly, increased numbers of both CD4+ and CD8+ 
CD28− memory T cells are associated with a poor outcome in 
renal and lung transplant patients (105–108). A recent report by 
Espinosa et al. identified yet another population of CD57+CD4+ T 
cells as potential mediators of belatacept-resistant renal allograft 
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rejection. These cells are more common in patients with kidney 
failure, express high levels of adhesion molecules CD2, LFA-1, 
and VLA-4, downregulate CD28, and produce IFNγ, tumor 
necrosis factor alpha (TNFα), and granzyme B consistent with 
effector/memory phenotype (109).
Recent reports suggest that the pedigree of alloreactive 
memory T cells in a given recipient may have important practi-
cal implications. Using three different pathogens to generate 
donor-reactive memory T cells in a mouse model of skin 
transplantation, Badell et al. demonstrated that the sensitivity 
of memory T cells to immunosuppression is dependent on 
their origin (110). In this study, Tcm with a less differentiated 
phenotype were most sensitive to the effects of costimulatory 
blockade. Consistent with these findings, in vitro comparison of 
CMV- and alloreactive T cells suggested that virus-specific fully 
differentiated T cells secreting IFNγ, TNFα, and IL-2 simulta-
neously are more resistant to the effects of CTLA4-Ig, whereas 
tacrolimus inhibits responses by both allo- and virus-specific 
T cells (111).
In addition to blocking CD28/B7 costimulation, CTLA4-Ig 
also prevents signaling through CTLA-4, which can have 
negative effects on generation and functions of regulatory T cells 
(Tregs) (112–117). To circumvent this problem, several antago-
nistic anti-CD28 mAbs and Ab F(ab′)2 fragments have been 
generated and showed promise in animal transplantation models 
(118–121). The selective effects of these reagents on memory T 
cell subsets and the potential pathogenicity of CD28lo Temra 
cells during such therapies remain to be determined. Attempts 
to target another major costimulatory pathway, CD40/CD154, 
encountered early difficulties because of thromboembolic effects 
of anti-CD154 (CD40L) blocking antibodies (122). To avoid 
cross-linking CD154 that is highly expressed on platelets, an 
alternative approach has been the generation of non-activating 
anti-CD40 antibodies. Several such reagents have been suc-
cessfully tested in non-human primate recipients of renal and 
islet allografts (123–128).
In addition to CD28/B7 and CD40/CD154 costimulation, 
several other costimulatory pathways may play a role in effector/
memory T cell functions. Inhibition or genetic lack of ICOS/
B7RP-1, CD134/CD134L, CD70/CD27, or CD137/CD137L 
improved allograft survival even in donor-sensitized recipients, 
or after delayed administration which allowed initial priming of 
donor-reactive T cells [reviewed in Ref. (129)]. It was revealed 
that these costimulatory pathways might control distinct aspects 
of the alloimmune response. For example, blocking anti-CD134L 
mAb inhibits proliferation of effector T cells while supporting the 
survival of Tregs (71, 130). Conversely, signaling through CD134 
inhibits immunosuppressive properties of FoxP3+ Tregs and 
promotes allograft rejection (131, 132). ICOS/B7RP-1 blockade 
of resting memory CD4+ T cells inhibits their helper functions 
and decreases alloantibody production. In contrast, circulating 
memory CD8+ T cells are ICOSlo, but rapidly upregulate ICOS 
surface expression upon graft infiltration. These examples 
demonstrate that the complexity of costimulatory pathways 
governing alloimmune responses must be considered when 
costimulatory blockade is used as part of immunosuppression 
regimen.
Limiting Trafficking of Alloreactive 
Memory T Cells
While preventing memory T cell entrance into graft tissue 
should improve transplant outcome, the attempts to neutralize 
chemokines or chemokine receptors such as CCR5 or CXCR3 
did not live up to the initial expectations, most likely due to 
the redundancy of chemokine/receptor network. On other 
hand, reagents blocking LFA-1 (leukocyte function-associated 
antigen-1, an αLβ2 integrin) and VLA-4 (very late antigen-4, an 
α4β1 integrin) have been demonstrated to prolong allograft sur-
vival in experimental transplantation [reviewed in Ref. (133)]. 
Treatment with either anti-LFA-1 or anti-VLA-4 blocking mAbs 
prolonged skin allograft survival in a mouse model of costimu-
latory blockade-resistant rejection by memory CD8+ T cells 
(134). In another study, pretransplant treatment with anti-LFA-1 
mAbs inhibited early infiltration of endogenous donor-reactive 
memory CD8+ T cells into cardiac allografts, and significantly 
prolonged allograft survival (135). These findings suggest that a 
short course of integrin blockade may be instrumental in con-
trolling T cell memory while avoiding side effects of long-term 
treatments.
COnCLUDing ReMARKS
While other types of immunologic memory lymphocytes such 
as memory B cells, preexisting alloantibodies, and “innate 
memory” described for NK cells and macrophages can impact 
transplant outcomes, in this review, we focused exclusively 
on T cell memory. It is now firmly established that alloreac-
tive memory T cells accelerate allograft rejection and prevent 
transplant tolerance. However, the implementation of accu-
mulated experimental knowledge in clinical transplantation 
is impeded by several factors. First, the diagnostics of T cell 
allosensitization in transplant candidates is problematic. Due 
to heterogeneity in phenotype and functions of memory T 
cells, complementary tests will be required including analyses 
of cytokine producing, cytotoxic, and follicular helper T cells. 
The resulting information is likely to be complex and hard to 
use in clinical decision-making. Second, memory T cells in 
humans are sampled only in peripheral blood. So far, there is 
no information on pathogenicity of tissue-resident alloreactive 
memory T cells. Third, memory T cell susceptibility to immu-
nosuppression may depend on their origins. As immunological 
histories of individuals are difficult to trace, the situation may 
arise when patients with similar T cell memory profile require 
distinct treatment strategies. Finally, despite rapidly accumu-
lating data on alloreactive T cell memory, the discrepancies 
between animal models and transplantation in human patients 
are profound. Ideally, animal transplantation models approxi-
mating clinical situation should take into account frequencies 
of total and donor-reactive memory T cells in different spe-
cies, time of graft cold ischemia storage, and the presence of 
DSA in recipient serum. Including these considerations into 
experimental design will facilitate the development of novel 
approaches to control memory T cells and improve transplant 
survival in sensitized recipients.
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